Dasiglucagon

Summary

Dasiglucagon is a synthetic analogue of human glucagon that has been formulated for ready‑to‑use subcutaneous injection. It is approved in the United States for the rapid treatment of severe hypoglycaemia in patients with diabetes, including children aged six years and older. By replacing the deficient endogenous glucagon during insulin‑induced low blood glucose, dasiglucagon quickly restores normal plasma glucose levels without the need for reconstitution.

Mechanism of Action

Dasiglucagon binds to the glucagon receptor on hepatocytes, activating adenylate cyclase and raising intracellular cAMP. This stimulates glycogenolysis and gluconeogenesis, leading to a rapid increase in hepatic glucose output and a rise in blood glucose. The peptide incorporates amino‑acid substitutions that confer enhanced stability in aqueous solution, allowing faster absorption after subcutaneous injection compared with native glucagon.

What the Research Shows

Regulatory filings reported that dasiglucagon received its first U.S. approval in 2021 for severe hypoglycaemia. Phase‑3, double‑blind, placebo‑controlled trials in children (6–17 years) and adults with type‑1 diabetes demonstrated a median time to glucose recovery of about 10 minutes, with 99 % of participants achieving recovery within 15 minutes. A meta‑analysis of five randomized trials found dasiglucagon shortened recovery time versus placebo (≈‑25 min) and oral glucose (≈‑15 min), but showed no statistically significant advantage over conventional glucagon. Review articles note its greater aqueous stability, higher absorption rate, and longer plasma half‑life relative to reconstituted glucagon, while safety data from the same trials report mainly mild gastrointestinal symptoms.

Reported Benefits

Clinical trials indicate dasiglucagon provides a faster glucose rescue than placebo or oral glucose and is comparable in speed to traditional glucagon. Its ready‑to‑use aqueous formulation eliminates the need for reconstitution, simplifying emergency administration. Pharmacokinetic studies show higher absorption and a longer half‑life, potentially reducing dosing variability. The drug is approved for use in both children and adults, expanding treatment options for severe hypoglycaemia.

Limitations of the Evidence

Evidence does not demonstrate superiority over conventional glucagon in head‑to‑head comparisons, and the meta‑analysis reported no significant difference in recovery time. Available data are limited to short‑term outcomes in type‑1 diabetes; long‑term safety and efficacy in other populations (e.g., type‑2 diabetes, congenital hyperinsulinism) remain unstudied. Most published information derives from phase‑3 trials and reviews rather than large post‑marketing surveillance.

Safety Considerations

The most frequently reported adverse events are nausea, vomiting, headache, and injection‑site pain. In the pivotal trials no serious safety signals were observed, and the overall tolerability was described as acceptable. As with all glucagon receptor agonists, caution is advised in patients with pheochromocytoma or severe cardiovascular disease, although such contraindications were not explicitly detailed in the cited abstracts.

How It Is Administered

Dasiglucagon is administered by subcutaneous injection using a single‑dose autoinjector or a prefilled syringe. The formulation is a ready‑to‑use aqueous solution that does not require reconstitution, allowing rapid delivery in emergency settings.

Routes of Administration

Goals & Uses

• Severe hypoglycemia rescueGlycemic Emergency ManagementHigh
• Hypoglycemia treatment in congenital hyperinsulinismEndocrine Disorder ManagementModerate
• Prevention of exercise-induced hypoglycemiaHypoglycemia PreventionLow

Contraindications

• Prolonged fasting or starvationNutritionalModerate
• Known hypersensitivity to dasiglucagon or excipientsAllergyHigh
• InsulinomaEndocrine TumorModerate
• PheochromocytomaEndocrine TumorHigh
• GlucagonomaEndocrine TumorHigh
• Hypersensitivity to dasiglucagon or excipientsAllergyHigh

Adverse Effects

• HypertensionCardiovascularUncommonHigh blood pressure
• Injection site reactionsLocalCommon
• Injection site painLocalCommonPain at the injection site
• Hypersensitivity/anaphylaxisImmunologicalRare
• HeadacheNeurologicCommonPain in the head or upper neck
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• VomitingGastrointestinalCommonForceful expulsion of stomach contents

Drug Interactions

• InsulinLowMay increase risk of low blood sugar
• Beta‑blockersModerate
• Beta-blockersModerate
• WarfarinModerate
• Other glucagon receptor agonistsModerate

Population Constraints

• PregnancyReproductive SafetyRelative
• Hepatic impairmentOrgan FunctionRelative
• Adrenal insufficiencyEndocrineRelative
• Age <2 yearsPediatricAbsolute
• Children under 6 years of agePediatricAbsolute

Regulatory Status

• European UnionUnapprovedPending evaluation; not yet authorized.
• United StatesApprovedApproved: Severe hypoglycemia in diabetes (≥2 years)Approved as Zegalogue, subcutaneous injection.
• United KingdomUnknownPost-Brexit regulatory status uncertain; approval may follow EU decision via MHRA.

FDA‑approved (2021) as Zegalogue for patients ≥2 years; not yet approved in the EU.

Evidence & Sources

• Dasiglucagon: First Approval
  Journal ArticleModerateBlair HA2021-01-01T00:00:00.000000Z
• Dasiglucagon for the Treatment of Insulin-induced Hypoglycemia in Patients with Type 1 Diabetes Mellitus: A Meta-analysis
  Journal ArticleHighMaji S, Mohanty RR, Maiti R2023-01-01T00:00:00.000000Z
• Dasiglucagon: an effective medicine for severe hypoglycemia
  Journal ArticleModerateXu B, Tang G, Chen Z2021-01-01T00:00:00.000000Z
• Dasiglucagon: A Novel Ready-to-Use Treatment for Severe Hypoglycemia
  Journal ArticleModerateGoodhart AL2023-01-01T00:00:00.000000Z
• Evaluating dasiglucagon as a treatment option for hypoglycemia in diabetes
  Journal ArticleModerateLi S, et al.2020-01-01T00:00:00.000000Z

Frequently Asked Questions